The promise and reality of cancer gene therapy

[21] Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene [J]. HUMAN GENE THERAPY, 1996, 7 (02) : 141 - 148

[22] INTERLEUKIN-2 PRODUCTION BY TUMOR-CELLS BYPASSES T-HELPER FUNCTION IN THE GENERATION OF AN ANTITUMOR RESPONSE [J]. CELL, 1990, 60 (03) : 397 - 403

[23] THERAPEUTIC EFFECT OF A RETROVIRAL WILD-TYPE P53 EXPRESSION VECTOR IN AN ORTHOTOPIC LUNG-CANCER MODEL [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (19) : 1458 - 1462

[24] Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4(+)-mediated rejection of established tumors [J]. HUMAN GENE THERAPY, 1997, 8 (04) : 477 - 488

[25] GANSBACHER B, 1990, CANCER RES, V50, P7820

[26] INTERLEUKIN-2 GENE-TRANSFER INTO TUMOR-CELLS ABROGATES TUMORIGENICITY AND INDUCES PROTECTIVE IMMUNITY [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (04) : 1217 - 1224

[27] Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53 [J]. MOLECULAR CARCINOGENESIS, 1995, 14 (04) : 275 - 285

[28] Hamel W, 1996, CANCER RES, V56, P2697

[29] Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20): : 1442 - 1455

[30] ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [J]. NATURE MEDICINE, 1997, 3 (06) : 639 - 645

[21] Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene [J]. HUMAN GENE THERAPY, 1996, 7 (02) : 141 - 148

[22] INTERLEUKIN-2 PRODUCTION BY TUMOR-CELLS BYPASSES T-HELPER FUNCTION IN THE GENERATION OF AN ANTITUMOR RESPONSE [J]. CELL, 1990, 60 (03) : 397 - 403

[23] THERAPEUTIC EFFECT OF A RETROVIRAL WILD-TYPE P53 EXPRESSION VECTOR IN AN ORTHOTOPIC LUNG-CANCER MODEL [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (19) : 1458 - 1462

[24] Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4(+)-mediated rejection of established tumors [J]. HUMAN GENE THERAPY, 1997, 8 (04) : 477 - 488

[25] GANSBACHER B, 1990, CANCER RES, V50, P7820

[26] INTERLEUKIN-2 GENE-TRANSFER INTO TUMOR-CELLS ABROGATES TUMORIGENICITY AND INDUCES PROTECTIVE IMMUNITY [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (04) : 1217 - 1224

[27] Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53 [J]. MOLECULAR CARCINOGENESIS, 1995, 14 (04) : 275 - 285

[28] Hamel W, 1996, CANCER RES, V56, P2697

[29] Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20): : 1442 - 1455

[30] ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [J]. NATURE MEDICINE, 1997, 3 (06) : 639 - 645